Page 80 - GTM-2-4

Global Translational Medicine

ORIGINAL RESEARCH ARTICLE
Prognostic evaluation of relapse based on

squamous cell carcinoma antigen, CXCR2, and
CD44V6 blood levels in patients with Stage I–II

squamous cell lung cancer

1
1
1
Anatoli D. Tahanovich *, Mikalai M. Kauhanka , Zhanna A. Rutkovskaya ,
1
Ekaterina A. Khotko , Oxana V. Gotko , and Violetta I. Prokhorova 2
2
1 Department of Biological Chemistry, Medical Faculty of International Students, Belarusian State
Medical University, Minsk, Belarus
2 Department of Laboratory Diagnostics, N.N. Alexandrov National Cancer Center of Belarus, a/g
Lesnoy, Minsk, Belarus

Abstract

Lung cancer, the leading cause of cancer-related mortality, predominantly exists as
non-small cell lung cancer, accounting for approximately 85% of cases and comprising
adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma as the
three most prevalent histological subtypes. This study focused on investigating
pre- and post-operative concentrations of SCC antigen in blood serum, as well as the
percentage of CXCR2-containing lymphocytes and CD44v6-containing monocytes
in blood cell populations among patients with Stages I–II squamous cell lung cancer
*Corresponding author:
Anatoli D. Tahanovich (SCLC) within 1 year after tumor resection. The primary objective was to assess their
(ataganovich@gmail.com) potential for predicting relapse. The study cohort comprised 57 patients (32 men
Citation: Tahanovich, AD, and 25 women) with newly diagnosed squamous cell lung cancer (21 at stage I
Kauhanka MM, Rutkovskaya ZA, and 36 at stage II). Following tumor resection, categorized as R0 in terms of surgical
et al., 2023, Prognostic evaluation intervention, all parameters were examined before surgery and at 3 weeks, 3 months,
of relapse based on squamous cell
carcinoma antigen, CXCR2, and and 6 months postoperatively. Analysis revealed that the probability of relapse could
CD44V6 blood levels in patients be accurately predicted, ranging from 68.4% to 89.5%, based on differences in SCC
with Stage I–II squamous cell lung antigen concentration, the percentage of lymphocytes with CXCR2, and monocytes
cancer. Global Transl Med, 2(4):
2209. with the CD44v6 receptor during various post-operative intervals. Subsequent
https://doi.org/10.36922/gtm.2209 regression analysis and the formulation of a combined model incorporating the above-
mentioned parameters led to an enhanced predictive value for tumor recurrence,
Received: November 8, 2023
Accepted: December 18, 2023 reaching 96.5% accuracy (with specificity at 95.6% and sensitivity at 100%). These
Published Online: December 28, 2023 results indicate the potential utility of the combined model as an additional marker
Copyright: © 2023 Author(s). for predicting postoperative relapse in patients with Stage I–II SCLC.
This is an Open-Access article
distributed under the terms of the
Creative Commons Attribution Keywords: Squamous cell lung cancer; Squamous cell carcinoma; CXCR2; CD44v6; Post-
License, permitting distribution, operative relapse; Prognosis
and reproduction in any medium,
provided the original work is
properly cited.
Publisher’s Note: AccScience
Publishing remains neutral with 1. Introduction
regard to jurisdictional claims in
published maps and institutional Lung cancer stands as the primary contributor to cancer-related mortality in men, with
[1]
affiliations. women ranking it as the second leading cause . Non-small cell lung cancer (NSCLC)

Volume 2 Issue 4 (2023) 1 https://doi.org/10.36922/gtm.2209